title: [Photodynamic therapy with verteporfirin in corneal neovascularization].
abstract: OBJECTIVE
  to evaluate vascular involution of corneal neovessels followed by the application of photodynamic therapy (PDT) verteporfirina.
  
  
  METHODS
  Prospective, longitudinal, case series. Fifty eyes of 49 candidate patients to partial penetrating keratoplasty (PPK) also called corneal transplant (CT) at risk of corneal neovascularization (CN) of two or more quadrants and which were previous treated with intravenous PDT. The monitoring was carried out with photographic control of the anterior segment assessing adverse effects and development of CN.
  
  
  RESULTS
  The length of the CN before and after PDT were 4.39 ± 2.24 vs 3.71 ± 2.48 (p < 0.0001) respectively. This involution was maintained after two months of follow up. One eye (2 %) presented changes Keratometry (keratometric astigmatism). Of the total 45 (90 %) of patients who showed a reduction in the CN, had revascularization within the following six months of intervention.
  
  
  CONCLUSIONS
  the PDT with verteporfirina is effective and safe for decreasing the length of the CN, without local and systemic adverse effects. However it is suggested to schedule the surgery two months after to permit revascularization.
authors.affiliation: Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Distrito Federal, México. karlaverdiguel@hotmail.com
authors.forename: Karla
authors.initials: K
authors.lastname: Verdiguel-Sotelo
authors.forename: Adriana
authors.initials: A
authors.lastname: Hernández-López
authors.forename: Pedro Iván
authors.initials: PI
authors.lastname: González-Camarena
authors.forename: Rebeca
authors.initials: R
authors.lastname: Devereux-García
authors.forename: Marcos Sebastián
authors.initials: MS
authors.lastname: Pineda-Espinosa
authors.forename: Rocío
authors.initials: R
authors.lastname: Gómez-Dávila
mesh_terms: D016510:Corneal Neovascularization / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D011446:Prospective Studies; D000077362:Verteporfin
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin